1.
Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...
2.
3.
4.
5.
6.
7.
log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males.
log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males.
IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings
Sensitization to isobornyl acrylate in a tertiary Belgian hospital.
8.
9.
Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients.
Coût croissant de l'insulinothérapie en Belgique. De l'analyse critique de la situation a la recherche de solutions pratiques. ; Increasing cost of insulin therapy in Belgium. From...
Established and novel gender dimorphisms in type 2 diabetes mellitus: Insights from a multiethnic cohort.
Classification of Recombinant Biologics in the EU: Divergence between National Pharmacovigilance Centers
Le medicament du mois. Sitagliptine (Januvia): incretinopotentiateur indique comme insulinosecretagogue dans le traitement du diabete de type 2. ; Sitagliptine (Januvia): incretin...